HIV Vaccines

艾滋病毒疫苗

• 批准号: 9065066
• 负责人: DAVID L. WOODLAND
• 金额: $ 2.16万
• 依托单位: KEYSTONE SYMPOSIA
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-01-01 至 2016-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9065066
• 关键词: AIDS prevention; Active Immunization; Address; Adjuvant; Antibodies; Antibody Response; Antigens; Area; Awareness; B-Lymphocytes; Basic Science; California; Clinical Trials; Complex; Development; Epitopes; Equilibrium; Event; Future; Goals; Growth; HIV; HIV Infections; HIV vaccine; Health Priorities; Immunity; Immunoglobulins; Immunologics; Immunotherapy; Infection; Infection prevention; Intervention; Knowledge; Learning; Mucosal Immunity; Outcome; Passive Immunization; Pathogenesis; Pathway interactions; Play; Polysaccharides; Prevention; Prevention strategy; Productivity; Regulatory Pathway; Research; Research Personnel; Risk; Role; Scientist; Specificity; Staging; Structure; Therapeutic; Time; Traction; Translating; Translational Research; Vaccine Design; Vaccines; Viral Antibodies; Work; base; career; global health; graduate student; interest; meetings; neutralizing antibody; nonhuman primate; novel vaccines; posters; preclinical evaluation; preclinical study; preclinical trial; prevent; public health relevance; research clinical testing; research study; symposium; treatment strategy; vector; viral transmission

 DESCRIPTION (provided by the applicant): Support is requested for a Keystone Symposia meeting entitled HIV Vaccines, organized by David C. Montefiori and Mario Roederer. The meeting will be held in Olympic Valley, California from March 20-24, 2016. The development of a safe and effective HIV vaccine remains a major global health priority and a complex problem to solve. Current efforts emphasize an ability to elicit systemic and mucosal antibody responses capable of preventing the acquisition of infection. Evidence from multiple passive transfer experiments in nonhuman primates, as well as from studies of immunologic correlates of modest efficacy in the RV144 Thai trial, support the notion that both neutralizing and non-neutralizing antibodies have potential to prevent infection. Major advances have been made in understanding the epitopes, structures and evolutionary pathways of broadly neutralizing antibodies, leading to new avenues to pursue for vaccine design. The extraordinary breadth and potency of some recently discovered neutralizing antibodies has generated additional interest in potential therapeutic applications, including cure strategies. There has also been a steady increase in knowledge of other types of antiviral antibodies and their effector functions that may be important for vaccines. This meeting aims to cover a range of topics including: 1) Initial virus transmission events for vaccine intervention, 2) Non-neutralizing antibody correlates of sterilizing immunity; 3) Epitopes, structures and ontogeny of broadly neutralizing antibodies; 4) Novel vaccine concepts for broadly neutralizing antibody induction; and 5) Immunotherapy. Emphasis will be placed on recent unpublished findings in key areas that hold the greatest promise for rapid progress toward an effective vaccine. Opportunities for interdisciplinary interactions will be significantly enhanced by the concurrent meeting on HIV Persistence: Pathogenesis and Eradication, which will share Keynote addresses and two plenary sessions with this meeting.

 描述（由申请人提供）：请求对由大卫C.蒙特菲奥里和马里奥·罗德勒会议将于2016年3月20日至24日在加州奥林匹克谷举行。开发安全有效的艾滋病毒疫苗仍然是全球卫生的一个主要优先事项，也是一个有待解决的复杂问题。目前的努力强调的能力，引起全身和粘膜抗体反应，能够防止感染的收购。来自非人灵长类动物中的多个被动转移实验以及来自RV 144 Thai试验中适度功效的免疫学相关性研究的证据支持中和和非中和抗体都具有预防感染的潜力的观点。在了解广泛中和抗体的表位、结构和进化途径方面取得了重大进展，为疫苗设计开辟了新的途径。一些最近发现的中和抗体的非凡的广度和效力已经在潜在的治疗应用中产生了额外的兴趣，包括治愈策略。对其他类型的抗病毒抗体及其效应子功能的了解也在稳步增加，这对疫苗可能很重要。本次会议旨在涵盖一系列主题，包括：1）初始病毒 传播事件的疫苗干预，2）非中和抗体相关的杀菌免疫; 3）表位，结构和个体发育的广泛中和抗体; 4）新的疫苗概念广泛中和抗体诱导;和5）免疫疗法。重点将放在最近未发表的研究结果，在关键领域，持有最大的希望，迅速取得进展，以有效的疫苗。同时举行的“艾滋病毒持续存在：发病机制和根除”会议将大大增加跨学科互动的机会，该会议将与本次会议分享主旨发言和两次全体会议。